glp 1 receptors Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide Receptor Agonists: A Scoping Review GLP-1 Receptor Agonists as Treatments

Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments

The three year absolute risk was 2.4% (95% CI 2.1% to 2.7%) lower for SGLT-2 inhibitors than DPP-4 inhibitors (4.6% v 7.0%), 1.8% (1.4% to 2.1%) lower for GLP-1 receptor agonists than DPP-4 inhibitors (5.7% v 7.5%), and 1.2% (0.9% to 1.5%) lower for SGLT-2 inhibitors than GLP-1 receptor agonists (4.7% v 6.0%)

W.et al (2023)

Is Pomegranate a legitimate GLP-1 provider

First and only anti-CD20 monoclonal antibody proven to deliver renal response benefits in a Phase III trial Twice-yearly dosing and a 90-minute infusion time Offers new hope to the 1.7 million people worldwidemostly women of colour and childbearing age affected by lupus nephritis #Roche #FDAApproval #LupusNephritis #Intellectt #Biopharma #MedicalInnovation #MonoclonalAntibody #DrugDevelopment #ClinicalTrials #Gazyva #HealthcareInnovation #LifeSciences To view or add a comment, sign in 4,021 followers